Vixtimotamab (AMV-564; TandAb T564) is a bispecific tetravalent tandem diabody (TandAb) designed to simultaneously target human CD33 and human CD3 antigens. This unique configuration facilitates the recruitment and activation of T cells against CD33-expressing cells, making it a valuable tool in the study of acute myeloid leukemia (AML). Vixtimotamab's dual targeting mechanism offers a promising approach for elucidating the interactions between immune cells and leukemia cells, providing significant insights into therapeutic strategies for AML.
Vixtimotamab (AMV-564; TandAb T564) is a bispecific tetravalent tandem diabody (TandAb) designed to simultaneously target human CD33 and human CD3 antigens. This unique configuration facilitates the recruitment and activation of T cells against CD33-expressing cells, making it a valuable tool in the study of acute myeloid leukemia (AML). Vixtimotamab's dual targeting mechanism offers a promising approach for elucidating the interactions between immune cells and leukemia cells, providing significant insights into therapeutic strategies for AML.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
